Your session is about to expire
← Back to Search
ITIL-168 for Melanoma (DELTA-1 Trial)
DELTA-1 Trial Summary
This trial is testing a new treatment for melanoma that uses the patient's own immune cells.
- Melanoma
DELTA-1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDELTA-1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DELTA-1 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA given its blessing to ITIL-168?
"ITIL-168's safety was rated a 2 by our Power company team. Phase 2 trials have shown some evidence of safety, but there is no data currently backing the efficacy of ITIL-168."
Are we still looking for individuals to participate in this research?
"From what is publicly available on clinicaltrials.gov, it seems that this particular medical trial has stopped enrolling new patients. The first posting was on October 7th 2021 with the most recent update being November 1st 2022. However, there are 783 other trials which are still recruiting patients."
Could you please tell me how many hospitals are participating in this research?
"Trial sites for this research include University of Colorado - Anschutz Cancer Pavilion in Aurora, Colorado, UCLA Health-Westwood Cancer Care in Los Angeles, California, and Georgetown University Medical Center in Washington D.C., amongst 22 other locations."
Share this study with friends
Copy Link
Messenger